In addition to their classical role in inhibiting the cell cycle progression and proliferation of cancer cells, CDK4/6 inhibitors also activate the immune system by stimulating the upregulation of MHC I on the membrane of cancer cells and producing interferon (IFN) in RB‐dependent mechanism. Here, CDK4 is linked to cancer.